Truveta Research

Defining what’s possible and demonstrating the potential of Truveta

Truveta Research is a highly accomplished team of physician scientists, epidemiologists, applied scientists, and data analysts. Their focus is showcasing the possibilities of Truveta to empower researchers to study patient care and outcomes.   

The team focuses on studies that explore health equity, monitor public health, and emulate randomized clinical trials with real-world data to improve health outcomes. 

Research in action

Truveta Research recently used Truveta Studio to explore potential racial and ethnic disparities in COVID hospitalizations during different time periods throughout the pandemic.

Microsoft and Truveta Announcement


Changes in Minoxidil Prescribing After Media Attention About Oral Use for Hair Loss

On August 18, 2022, The New York Times published an article describing successful treatment experiences of several dermatologists and results of a small observational study of women with hair loss who received low-dose oral rather than topical minoxidil. We used prescription drug data to investigate changes in prescribing of oral minoxidil after the article, which was covered broadly by news and social media.

Read more on JAMA Network Open

The lasting effects of the pandemic: A time series analysis of first-time speech delays in kids under 5 years of age

Given the profound effects of the COVID-19 pandemic on the way individuals interact, we sought to understand if there was an increase in pediatric first-time speech and language delay diagnoses.

Read the pre-print on MedRxiv

Effect of vaccination on time till Long COVID, a comparison of two ways to model effect of vaccination and two outcome definitions

Long COVID, or post-COVID syndrome, is a constellation of symptoms observed in patients at least four weeks after COVID-19 infection. We analyzed the effect of COVID-19 vaccination status on risk of either developing Long COVID symptoms or being diagnosed with Long COVID.  Our results support the growing evidence that having complete a primary vaccination sequence is protective against the development of Long COVID symptoms or the diagnosis of Long COVID.

Read this pre-print on MedRxiv

Monitoring Report: Respiratory Viruses

This report contains current hospitalization trends associated with six common respiratory viruses: COVID-19, human metapneumovirus (HMPV), influenza virus, parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus. This report is intended to describe trends and comparisons of respiratory virus-associated hospitalizations in different demographic groups and across seasons.

Read more

Respiratory Syncytial Virus (RSV) Hospitalization Trends [Updated February 17, 2023]

This report contains current hospitalization trends associated with respiratory syncytial virus (RSV). We used a subset of Truveta Data to identify laboratory-confirmed RSV infections in children and adults. This report is intended to describe trends and comparisons of RSV-associated hospitalizations in different demographic groups and across seasons.

February (Updated February 17, 2023)

January (Updated January 13, 2023)

Download the supplemental materials

COVID Treatment and In-hospital Length of Stay Inequalities Between Race in the US Over Time

Demonstrated health inequalities persist in the United States. SARS-CoV-2 (COVID) has been no exception, with access to treatment and hospitalization differing across race or ethnic group. Here we aim to assess differences in treatment with remdesivir and hospital length of stay across four waves of the pandemic.

Read more on Frontiers

Risk of COVID-19 Breakthrough Infection and Hospitalization in Individuals with Comorbidities

Studies have shown that those with certain high-risk comorbidities such as diabetes, chronic kidney disease (CKD), chronic lung disease, or those with immunocompromising conditions have increased risk of hospitalization from COVID-19. Here we estimate the elevated risks of breakthrough infection and hospitalization in fully vaccinated individuals with comorbidities.

Read more